The company provides contract research and manufacturing services for global pharmaceutical firms, specializing in complex high-potency active ingredients and oncology treatments, while also selling specialty chemicals and Vitamin D analogues.
The company possesses a narrow moat based on high switching costs and regulatory barriers in the CDMO space, particularly for high-potency oncology drugs. However, this is contradicted by chronically low returns on capital (3% ROCE) and poor asset turnover, suggesting the technical expertise has not translated into economic power.
Management has invested heavily in global capacity, including a major sterile injectables plant in France and ADC expansions in Switzerland. These investments have significantly increased debt and depreciation without a commensurate rise in net profit, leading to poor return on equity.
The company collapsed under the weight of its own capital intensity as massive global expansions in France and Switzerland failed to generate the requisite cash flow to service its debt. The high goodwill balance, already inflated by currency fluctuations, eventually faced a catastrophic impairment that wiped out book value. As interest coverage remained dangerously thin, the promoter's personal liquidity dried up, ending the cycle of related-party bailouts and forcing a fire sale of assets to satisfy creditors.
RichFakir rates Dishman Carbogen Amcis Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Dishman Carbogen Amcis Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Dishman Carbogen Amcis Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Dishman Carbogen Amcis Ltd's fair value is about ₹31 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →